The Impact of an Adaptive Patient-centered Web Application on Medication Optimization in HFrEF Patients

Description

The SmartHF study is a 12-week prospective randomized controlled multicenter clinical trial. This study will investigate the efficacy of an adaptive web application to facilitate guideline-directed medical therapy (GDMT) optimization in HFrEF patients. Eligible participants will be randomized to the web application intervention or control in a 1:1 manner, stratified by site. The intervention is an adaptive medication optimization web application that extracts and analyzes the EHR data with a computable medication optimization algorithm. The algorithm provides a medication quality score and outputs medication optimization recommendations written in a patient -friendly manner.

Conditions

Heart Failure

Talk to us

Study Overview

On this page

Study Details

Study overview

The SmartHF study is a 12-week prospective randomized controlled multicenter clinical trial. This study will investigate the efficacy of an adaptive web application to facilitate guideline-directed medical therapy (GDMT) optimization in HFrEF patients. Eligible participants will be randomized to the web application intervention or control in a 1:1 manner, stratified by site. The intervention is an adaptive medication optimization web application that extracts and analyzes the EHR data with a computable medication optimization algorithm. The algorithm provides a medication quality score and outputs medication optimization recommendations written in a patient -friendly manner.

The Impact of an Adaptive Patient-centered Web Application on Medication Optimization in HFrEF Patients (SmartHF)

The Impact of an Adaptive Patient-centered Web Application on Medication Optimization in HFrEF Patients

Condition
Heart Failure
Intervention / Treatment

-

Contacts and Locations

Atlanta

Emory University, Grady Hospital, Atlanta, Georgia, United States, 30303

Ann Arbor

University of Michigan, Ann Arbor, Michigan, United States, 48109

Detroit

Henry Ford Hospital and Health System, Detroit, Michigan, United States, 48202

Ypsilanti

Trinity Healthcare St. Joseph Mercy Ann Arbor, Ypsilanti, Michigan, United States, 48197

Saint Louis

Washington University, Barns Jewish Hospital, Saint Louis, Missouri, United States, 63110

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age 18 years and older at screening
  • 2. Diagnosis of heart failure with a left ventricular ejection fraction (LVEF) \</= 40% (HFrEF)
  • 3. Have a general medicine provider or general cardiology provider for HFrEF
  • 4. Have internet access and access to their health system's patient portal
  • 5. Fluent in spoken and written English
  • 6. At least two of the following: systolic blood pressure ≥ 110mmg, potassium ≤ 5.5, serum creatinine ≤ 2.5, heart rate ≥ 70
  • 7. At least two eligible heart failure therapies (guideline-recommended BB, RASI, MRA, or SGLT2i) not yet initiated or below 50% of the target dose
  • 1. End-stage HF (hospice candidate)
  • 2. Actively treated cancer, except non-melanoma skin cancer
  • 3. Implanted ventricular assist device
  • 4. Current treatment with chronic inotropic therapy
  • 5. Patient's provider for HFrEF care is considered an advanced HF specialist
  • 6. Currently pregnant or intends to become pregnant during the study period
  • 7. Dialysis

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Michigan,

Study Record Dates

2026-06-01